Renata Enters Canadian Market with Oral Contraceptive Launch

Date:

Post View:

Renata Enters Canadian Market with Oral Contraceptive Launch

Toronto, Canada – Renata PLC has officially entered the Canadian pharmaceutical market with the launch of its first product: Desogestrel/Ethinylestradiol (0.15mg/0.03mg) oral contraceptive tablets.

The product, a fixed-dose combination of Desogestrel (a progestin) and Ethinylestradiol (an estrogen), is being introduced under the brand names Miley 21 and Miley 28. It will be commercialised through a strategic partnership with Ambicare Pharmaceuticals Inc., a Canadian company known for its portfolio of high-quality, niche generic products across multiple therapeutic areas.

The tablets are manufactured at Renata’s Health Canada-approved potent product facility, ensuring compliance with stringent quality and regulatory standards.

Renata also markets the same formulation in Bangladesh under the brand name Desolon.

This marks a significant milestone for Renata as it expands into North America, with plans to grow its product portfolio in the Canadian market.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_img

Popular

More like this
Related

KfW review mission begins assessment of LGED’s CRIMP-CReLIC activities

A review mission of the development partner German Development...

DSEX gains 60 points as turnover hits four-month high

The country's stock market continued its upward momentum on...

BGMEA estimates Tk 5,136cr losses from RMG unrest

Ongoing labour unrest in the readymade garment (RMG) sector...

AIBL becomes platinum sponsor of Blue Star team in BCB’s D-3 Trophy

Al-Arafah Islami Bank PLC has signed a Platinum Sponsorship...